Are There Any Targeted Therapies for IDH-Mutant Cancers?
Yes, targeted therapies have been developed to inhibit mutant IDH enzymes. Examples include Ivosidenib (AG-120) for IDH1-mutant AML and Enasidenib (AG-221) for IDH2-mutant AML. These inhibitors have shown promise in clinical trials, leading to partial or complete responses in a subset of patients. Ongoing research aims to extend these therapies to other IDH-mutant cancers.
